Gillian Woollett, MA, DPhil, senior vice president, Avalere Health, discusses how confirming "sufficient likeness" in biosimilar development can and should replace the current "totality of the evidence” approach to biosimilar development.
Interviews
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Prescription Access Crisis: 40% of GLP-1 RA Rx Are Unfilled
2
Guideline-Directed Medical Therapies in Heart Failure
3
Responsible Use of Energy-Based Treatments on Skin of Color: Eliot F. Battle, MD
4
Collaboration in Heart Failure Treatment
5
